Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Vitamin k pills could unclog arteries, new study hints

NCT ID NCT05259046

Disease control Sponsor: Bispebjerg Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether taking vitamin K (menaquinone-7) supplements can reduce calcium buildup in heart arteries and improve artery flexibility. Researchers will give 450 adults with early signs of artery calcification either vitamin K or a placebo for a period. The goal is to see if this simple supplement can lower heart disease risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

450 people

The number who actually took part.

Started

Jun 2022

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Detectable CAC (Agatson score \>=10) assessed by Cardiac Computed Tomography (CT) scan in the Inter99 20-year follow-up study Exclusion Criteria: * Manifest CVD (prior cerebral infarct, prior myocardial infarct, prior percutaneous coronary intervention or prior coronary artery bypass surgery) * Noise on the CT scan, which complicates an accurate assessment of CAC and interpretation of the CT scan. An example is a pacemaker * Current treatment with Vitamin K antagonist (VKA). * History of coagulation disorders (hemophilia, von Willebrand disease, sickle cell anemia) * Active malignant disease (ongoing treatment) * Previous surgical removal of the thyroid gland, or one or more of the parathyroid glands * Regular use of vitamin K supplements other than trial tablets * Pregnancy or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arterial stiffness are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary atherosclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arterial stiffness Coronary artery calcification

Contacts and locations

Locations

  • Center for Clinical Research and Prevention

    Copenhagen, Glostrup, DK-2600, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.